MX362804B - Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. - Google Patents

Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.

Info

Publication number
MX362804B
MX362804B MX2015005879A MX2015005879A MX362804B MX 362804 B MX362804 B MX 362804B MX 2015005879 A MX2015005879 A MX 2015005879A MX 2015005879 A MX2015005879 A MX 2015005879A MX 362804 B MX362804 B MX 362804B
Authority
MX
Mexico
Prior art keywords
capsaicinoid
formulations
administration
corticosteroid
treatment
Prior art date
Application number
MX2015005879A
Other languages
English (en)
Other versions
MX2015005879A (es
Inventor
Daniel Bucks
Philip J Birbara
Charles A Birbara
Mary Coughlin
Original Assignee
Vizuri Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vizuri Health Sciences Llc filed Critical Vizuri Health Sciences Llc
Publication of MX2015005879A publication Critical patent/MX2015005879A/es
Publication of MX362804B publication Critical patent/MX362804B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se dan a conocer formulaciones de capsaicinoides y métodos de tratamiento los cuales se pueden utilizar para tratar/atenuar el dolor en mamíferos. Típicamente, la administración es por vía de una inyección en un sitio discreto para proporcionar alivio al dolor durante un período de tiempo prolongado. Las formulaciones se administran en un vehículo farmacéuticamente aceptable. Las formulaciones incluyen un agente analgésico en una cantidad suficiente para atenuar los efectos de quemadura e hiperalgésicos de la administración de capsaicinoides. La invención también incluye un método para tratar el dolor por medio de la administración de un corticosteroide seguido por la administración de un capsaicinoide.
MX2015005879A 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. MX362804B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725161P 2012-11-12 2012-11-12
PCT/US2013/069711 WO2014075084A2 (en) 2012-11-12 2013-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use

Publications (2)

Publication Number Publication Date
MX2015005879A MX2015005879A (es) 2016-02-05
MX362804B true MX362804B (es) 2019-02-14

Family

ID=49880927

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013715A MX387113B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2015005879A MX362804B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013715A MX387113B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.

Country Status (9)

Country Link
US (2) US20140142073A1 (es)
EP (2) EP2916817B1 (es)
JP (1) JP6695140B2 (es)
KR (2) KR20200119351A (es)
CN (1) CN105101949A (es)
AU (1) AU2013341380B2 (es)
CA (1) CA2891218A1 (es)
MX (2) MX387113B (es)
WO (1) WO2014075084A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
CA2945818C (en) 2014-04-15 2022-05-03 Vizuri Health Sciences Llc Topical compositions comprising a capsaicinoid for pain relief, manufacture and use
JP6948762B2 (ja) * 2015-10-16 2021-10-13 株式会社マンダム Ｔｒｐｖ１活性抑制剤作用増幅用組成物
CN108697673A (zh) * 2016-01-22 2018-10-23 中枢疗法公司 用于治疗莫顿神经瘤疼痛的辣椒碱依次给予方法
EP3534961B1 (en) * 2016-11-02 2026-02-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2019018769A1 (en) * 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
CN111479565A (zh) * 2017-10-20 2020-07-31 艾克西化学公司 作为生物增强剂的合成辣椒碱类似物
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用
CN114903851A (zh) * 2021-02-10 2022-08-16 北京泰德制药股份有限公司 一种辣椒碱脂肪乳
CN118267355A (zh) * 2022-12-29 2024-07-02 南京清普生物科技有限公司 一种辣椒素的乳剂组合物及其制备方法和应用
WO2025153515A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Lyophilized resiniferatoxin
WO2025214431A1 (zh) * 2024-04-11 2025-10-16 泰励生物科技（上海）有限公司 负载辣椒素的透明质酸交联物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4702916A (en) * 1985-12-03 1987-10-27 Warner-Lambert Company Analgesic stick compositions
JPS63130540A (ja) * 1986-11-18 1988-06-02 Sunstar Inc 鎮痛用組成物
JPH0621063B2 (ja) * 1986-12-06 1994-03-23 サンスタ−株式会社 歯科用鎮痛剤組成物
DE69841907D1 (de) 1997-03-13 2010-11-04 James N Campbell Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
JP3022541B1 (ja) * 1999-01-11 2000-03-21 株式会社ヘルスサイエンスセンター 外用剤
US6573302B1 (en) * 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
AU2003299691B2 (en) 2002-12-18 2008-06-05 Algorx Pharmaceuticals, Inc. Administration of capsaicinoids
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
US20050085652A1 (en) 2003-04-08 2005-04-21 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
CA2569155A1 (en) 2004-06-02 2005-12-15 Sri International Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
JP2006298944A (ja) * 2004-11-05 2006-11-02 Maruishi Pharmaceutical Co Ltd インスリン様成長因子−１分泌促進剤
WO2006058140A2 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
EP1830836B1 (de) * 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
WO2006069452A1 (de) 2004-12-28 2006-07-06 Mestex Ag Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
EP2544652A2 (en) * 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
JP6105475B2 (ja) * 2010-10-22 2017-03-29 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法
EP2753319B1 (en) 2011-09-09 2018-04-11 Vizuri Health Sciences LLC A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof

Also Published As

Publication number Publication date
EP2916817B1 (en) 2018-09-12
MX2018013715A (es) 2019-07-29
US20190022110A1 (en) 2019-01-24
EP3446680A1 (en) 2019-02-27
MX2015005879A (es) 2016-02-05
CN105101949A (zh) 2015-11-25
KR20200119351A (ko) 2020-10-19
CA2891218A1 (en) 2014-05-15
US20140142073A1 (en) 2014-05-22
EP2916817A2 (en) 2015-09-16
AU2013341380A1 (en) 2014-05-15
JP6695140B2 (ja) 2020-05-20
AU2013341380B2 (en) 2018-04-26
KR20150084996A (ko) 2015-07-22
AU2013341380A2 (en) 2015-10-22
JP2015536998A (ja) 2015-12-24
WO2014075084A2 (en) 2014-05-15
WO2014075084A3 (en) 2014-07-10
MX387113B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
MX2015005879A (es) Formulaciones de capsaicinoides basadas en agua, y tratamiento en combinacion con un corticosteroide.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2017005875A (es) Metodos para tratar enfermedades oculares.
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
MX2015012879A (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
EA201590847A1 (ru) Новые ингибиторы rock
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CO2020001887A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
MX2015011347A (es) Tratamiento sistemico y topico combinado de tejidos con trastorno.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration